Satsuma Pharmaceuticals Announces $86 Million IPO to Advance Migraine Drug STS101

On August 19, 2019, VCBeat (WeChat ID: vcbeat) learned from foreign media reports that biopharmaceutical company Satsuma Pharmaceuticals (Satsuma) announced plans for an initial public offering (IPO), aiming to raise $86 million. The company has currently filed a preliminary prospectus.

It is reported that Satsuma had previously completed two rounds of financing. The company raised $62 million in its Series B round in April 2019 and $12 million in its Series A round in January 2017.

Satsuma, a biotechnology and pharmaceutical company founded in 2016 and headquartered in California, USA, is dedicated to developing novel therapies for conditions such as migraine to improve patient outcomes. The Company primarily conducts its operations in California and North Carolina, among other locations in the United States.

Migraine is a chronic neurovascular disorder that predominantly affects middle-aged and young adults, particularly women. It is the most common type of primary headache in clinical practice and often has a familial genetic background. The main clinical symptom is moderate to severe unilateral headache, which may be accompanied by nausea and vomiting. Headache can be aggravated by light or sound stimulation or daily activities, while a quiet environment and adequate rest can alleviate the pain.

Satsuma boasts an experienced management team. John Kollins, the company’s co-founder and Chief Executive Officer, has nearly 30 years of experience in the biopharmaceutical industry, having held senior management positions at several biopharmaceutical companies, including Transcept Pharmaceuticals, Renovis, Athena Neurosciences, and Elan Pharmaceuticals. Detlef Albrecht, Satsuma’s Chief Medical Officer, holds M.D. and Ph.D. degrees from RWTH Aachen University in Germany and is dedicated to developing drugs for various indications, including urology, pain, oncology, renal diseases, and cardiovascular diseases.

Satsuma has developed its lead candidate, STS101, by combining the vasoconstrictor dihydroergotamine (DHE) with a nasal delivery technology. Therapies based on this drug offer several advantages over other migraine treatments, such as triptans. DHE effectively alleviates migraines by constricting blood vessels in the brain, while the nasal delivery technology facilitates rapid drug absorption and enhances bioavailability.

Researchers have conducted multiple preclinical studies and risk assessments on STS101, demonstrating that the drug effectively addresses the medical needs of migraine patients. Clinical data further indicate that STS101 exhibits a rapid onset of action after administration and is well tolerated by patients.

This July, Satsuma presented findings from its Phase 1 clinical trial of STS101 at the American Headache Society (AHS) Annual Scientific Meeting, including data on pharmacokinetic profiles, safety, and patient tolerability.

Dr. Albrecht stated, “Following administration, STS101 reaches the minimum effective concentration within 10 minutes and maintains therapeutic plasma levels for a sustained period. Clinical trials have demonstrated that the drug exhibits stable pharmacokinetics and a favorable safety profile. We will continue to conduct further research on STS101.”

(Compiled by Xu Xiaoxue)